{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:06:19Z","timestamp":1790885179007,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Despite significant therapeutic advances in multiple myeloma (MM), outcomes in patients with plasma cell leukemia (PCL) remain dismal. We conducted a multicenter retrospective analysis of patients with PCL who were treated with the B-cell maturation antigen\u2013directed chimeric antigen receptor T-cell (CAR-T) products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We identified 34 patients; 19 patients received ide-cel and 15 received cilta-cel. With a median follow-up of 11.9 months, the overall median progression-free survival (mPFS) was 9.0 months (95% confidence interval [CI], 4-15) and the median overall survival (mOS) was 13.0 months (95% CI, 8 to not estimable [NE]). The 1-year cumulative incidence of progression or death was 72%, and the 1-year cumulative incidence of death was 47%. Patients who received cilta-cel had a longer mPFS (19.0 months vs 6.0 months) and mOS (&amp;gt;23 months [NE] vs 9.0 months) when compared with those treated with ide-cel. Similarly, the 1-year cumulative incidence of disease progression or death was 37.5% (95% CI, 17.4-68.5) with cilta-cel, whereas all patients treated with ide-cel progressed or died within 12 months of infusion. The rates of hematologic and nonhematologic toxicities were similar between patients treated with cilta-cel and those treated with ide-cel and were consistent with those reported in patients with MM. In this first multicenter study that evaluated patients with PCL who were treated with standard-of-care CAR-T products, we show that CAR-T is safe, feasible, and associated with improved outcomes when compared with historic standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016966","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:13:19Z","timestamp":1756404799000},"page":"6009-6018","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1084-953X","authenticated-orcid":false,"given":"Gliceida M.","family":"Galarza Fortuna","sequence":"first","affiliation":[{"name":"1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Peres","sequence":"additional","affiliation":[{"name":"2Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nazarenko","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna N.","family":"Hovanky","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avilla","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, University of Washington, Fred Hutch Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Gaballa","sequence":"additional","affiliation":[{"name":"9Division of Cancer Medicine, Department of Lymphoma-Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Forsberg","sequence":"additional","affiliation":[{"name":"11Division of Hematologic\/Oncology, University of Colorado Cancer Center, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-4442","authenticated-orcid":false,"given":"Amandeep","family":"Godara","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"12Hematologic Malignancies and Cellular Therapy Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"given":"Larry","family":"Anderson","sequence":"additional","affiliation":[{"name":"12Hematologic Malignancies and Cellular Therapy Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"13Division of Transplant and Cellular Therapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"14Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-6228","authenticated-orcid":false,"given":"Hashim","family":"Mann","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Purvey","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clark","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"16Department of Hematology & Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"17Division of Transplantation and Cellular Therapy, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise L.","family":"Pereira","sequence":"additional","affiliation":[{"name":"17Division of Transplantation and Cellular Therapy, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[{"name":"18Division of Hematology\/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher James","family":"Ferreri","sequence":"additional","affiliation":[{"name":"19Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"19Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"19Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"20Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Shambavi","sequence":"additional","affiliation":[{"name":"20Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"21Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[{"name":"22Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2025120910563243800_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-022-05058-5","article-title":"The emerging therapeutic landscape of relapsed\/refractory multiple myeloma","volume":"102","author":"Tanenbaum","year":"2023","journal-title":"Ann Hematol"},{"issue":"18","key":"2025120910563243800_bib2","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple myeloma-a promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"issue":"S1","key":"2025120910563243800_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5045\/br.2022.2022033","article-title":"Update on primary plasma cell leukemia","volume":"57","author":"Jung","year":"2022","journal-title":"Blood Res"},{"issue":"17","key":"2025120910563243800_bib4","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2025120910563243800_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-018-0059-6","article-title":"Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group","volume":"8","author":"Katodritou","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025120910563243800_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2021.01.002","article-title":"Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia","volume":"21","author":"Parrondo","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 16","key":"2025120910563243800_bib7","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2023.41.16_suppl.8014","article-title":"Plasma cell leukemia: a multicenter retrospective study of 150 patients","volume":"41","author":"Chineke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120910563243800_bib8","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3390\/cancers16112149","article-title":"A clinical perspective on plasma cell leukemia: a single-center experience","volume":"16","author":"Li","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025120910563243800_bib9","doi-asserted-by":"crossref","first-page":"2634853521999389","DOI":"10.1177\/2634853521999389","article-title":"Management of primary plasma cell leukemia remains challenging even in the era of novel agents","volume":"14","author":"Chaulagain","year":"2021","journal-title":"Clin Med Insights Blood Disord"},{"issue":"1","key":"2025120910563243800_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-023-03545-7","article-title":"Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review","volume":"118","author":"Obo","year":"2023","journal-title":"Int J Hematol"},{"key":"2025120910563243800_bib11","doi-asserted-by":"crossref","first-page":"1495233","DOI":"10.3389\/fimmu.2024.1495233","article-title":"Anti-BCMA and GPRC5D bispecific antibodies in relapsed\/refractory primary plasma cell leukemia: a case report","volume":"15","author":"Bernardi","year":"2024","journal-title":"Front Immunol"},{"issue":"11","key":"2025120910563243800_bib12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120910563243800_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120910563243800_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2025120910563243800_bib15","author":"National Cancer Institute","year":"2017"},{"issue":"4","key":"2025120910563243800_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2025120910563243800_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025120910563243800_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.6000\/1929-6029.2015.04.03.7","article-title":"Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study","volume":"4","author":"Liu","year":"2015","journal-title":"Int J Stat Med Res"},{"issue":"2","key":"2025120910563243800_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat"},{"issue":"1","key":"2025120910563243800_bib20","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2025120910563243800_bib21","volume-title":"IBM SPSS Statistics for Windows, (ed 29.0.2.0)","year":"2023"},{"key":"2025120910563243800_bib22","author":"R Development Core Team","year":"2024"},{"issue":"7","key":"2025120910563243800_bib23","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"2025120910563243800_bib24","author":"Mateos MVS-M","year":"25-28  2024"},{"issue":"23","key":"2025120910563243800_bib25","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"2025120910563243800_bib26","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025120910563243800_bib27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025120910563243800_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clml.2024.10.014","article-title":"Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: a single center retrospective study","volume":"25","author":"Shalaby","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2025120910563243800_bib29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek Myeloma Study Group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025120910563243800_bib30","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2024-210746","article-title":"The Differences between ide-cel and cilta-cel in relapsed myeloma at single cell resolution","volume":"144","author":"Fandrei","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120910563243800_bib31","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2023-182141","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy using a matching-adjusted indirect comparison","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120910563243800_bib32","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1182\/blood-2023-186163","article-title":"Using real-world remanufacturing and recollection data to optimize time-to-treatment in patients with out-of-specification ciltacabtagene autoleucel","volume":"142","author":"Bowden","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120910563243800_bib33","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1182\/blood-2024-194645","article-title":"Global manufacturing experience with idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma","volume":"144","author":"Sidana","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025120910563243800_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120910563243800_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","article-title":"Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson Cancer Center experience","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120910563243800_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br J Haematol"},{"issue":"10297","key":"2025120910563243800_bib37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025120910563243800_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120910563243800_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025120910563243800_bib40","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6009\/2423283\/blooda_adv-2025-016966-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6009\/2423283\/blooda_adv-2025-016966-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:56:45Z","timestamp":1765295805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/6009\/547019\/Safety-and-efficacy-of-BCMA-directed-chimeric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016966","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,11,26]]}}}